[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Dongzhimen Hospital, Beijing\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":304},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,12,0,[8,49,73,98,123,149,178,200,220,234,259,285],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100568832","phase-2-the-treatment-of-sepsis-induced-myocardial-dysfunction-with-yiqilishui-formula-100568832",false,"NCT06686355","The Treatment of Sepsis Induced Myocardial Dysfunction With Yiqilishui Formula","Double-blind Randomized Parallel Contrast Clinical Study of Yiqilishui Formula on Sepsis Induced Myocardial Dysfunction","YQSIMD","Inclusion Criteria\n\n1. Patients hospitalized in the ICU of Tongzhou Traditional Chinese Medicine Hospital and Dongzhimen Hospital of Beijing University of Chinese Medicine between January 2024 and December 2026.\n2. Patients diagnosed with SIMD and qi deficiency and water flooding syndrome.\n3. Aged 50 to 85 years.\n4. SOFA score: 2 to 12 points.\n5. Diagnosis of SIMD within 24 hours.\n6. Signed informed consent by the patient or their family.\n\nExclusion Criteria\n\n1. Subjects diagnosed with acute coronary syndrome.\n2. Subjects with heart failure caused by cardiomyopathies such as hypertrophic cardiomyopathy, dilated cardiomyopathy, myocardial amyloidosis, diabetic cardiomyopathy, or hypothyroid cardiomyopathy.\n3. Subjects with heart failure caused by structural heart abnormalities, arrhythmias, pulmonary heart disease, or cardiorenal syndrome.\n4. Subjects with severe primary diseases affecting survival, including uncontrolled, unresectable metastatic malignant tumors, hematologic diseases, and HIV.\n5. Subjects with liver or kidney dysfunction, with an individual SOFA score of ≥3 for liver or kidney function.\n6. Subjects who have used immunosuppressants continuously in the last 6 months or have undergone organ transplantation.\n7. Subjects who have used corticosteroids (equivalent to methylprednisolone ≥20mg\u002Fday) continuously within 7 days prior to enrollment.\n8. Subjects who have used Chinese herbal medicines or Chinese patent medicine replenishing qi, activating blood circulation and facilitating diuresis within 14 days prior to enrollment.\n9. Subjects deemed unable to take decoctions by clinicians.\n10. Pregnant or breastfeeding women.\n11. Subjects who have participated in other clinical trials within the last 30 days.\n12. Subjects deemed unable to complete or unsuitable for this study by the researchers (e.g., expected death within 48 hours or refusal of active treatment).","ALL","50 Years","85 Years",{"count":21,"type":22},80,"ESTIMATED","INTERVENTIONAL",[25],"PHASE2","The goal of this clinical trial is to learn if Chinese medicine - Yiqilishui formula works to treat sepsis-induced myocardial dysfunction (SIMD). It will also learn about the safety of Yiqilishui formula. The main questions it aims to answer are:\n\n* Compared with conventional western traetment alone, can supplementing conventional Western treatment with Yiqilishui formula better improve the heart function and reduce mortality of participants with SIMD?\n* What medical problems do participants have when taking Yiqilishui formula? Researchers will compare Yiqilishui formula to a placebo (a look-alike substance that contains no drug) to see if Yiqilishui formula works to treat SIMD.\n\nParticipants will:\n\n* Take Yiqilishui formula granules or placebo twice daily for 7 days, while receiving standard conventional Western treatment.\n* Undergo blood drawing, electrocardiogram and transthoracic echocardiography at enrollment, on the 3rd day, the 7th day, and the 14th day after enrollment.",[28],"Sepsis Induced Myocardial Dysfunction",[30,31,32,33,34,35],"sepsis","myocardial dysfunction","SIMD","Yiqilishui formula","Double-blind randomized","clinical study","RECRUITING","2026-03-25",{"date":39,"type":40},"2026-03-30","ACTUAL",{"date":42,"type":40},"2024-11-20",{"date":44,"type":22},"2026-12-31",{"name":46,"class":47},"Dongzhimen Hospital, Beijing","OTHER",1,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":57,"targetDuration":59,"studyType":60,"phases":4,"briefSummary":61,"conditions":62,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":72,"locationsCount":48},"100619242","registry-study-of-cerebral-small-vessel-disease-100619242","NCT07342075","Registry Study of Cerebral Small Vessel Disease","Real-world Patient Registry Study of Cerebral Small Vessel Disease","DZM-CSVD-R","Inclusion Criteria:\n\n1. Age above 50 years (including 50-year-old);\n2. MRI confirmed the presence of typical imaging changes of CSVD;\n3. Voluntary participation in the study and be willing to sign the Informed Consent Form.\n\nExclusion Criteria:\n\n1. Patients with acute ischemic stroke or acute intracranial hemorrhage (e.g., epidural hematoma, subdural hematoma, subarachnoid hemorrhage, intracerebral hemorrhage, etc.) or a history of cerebral infarction (non-lacunar) or intracranial hemorrhage within the past 3 months;\n2. Significant non-vascular white matter lesions (e.g., multiple sclerosis, adult-onset leukoencephalopathy, metabolic encephalopathy, etc.);\n3. Patients with a history of cognitive impairment due to other causes (e.g., normal pressure hydrocephalus, Alzheimer's disease, Parkinson's disease, multiple sclerosis, encephalitis, etc.);\n4. Severe hepatic, renal, or cardiac insufficiency (ALT or AST \\>2 times the upper limit of normal, or serum creatinine \\>1.5 times the upper limit of normal, or New York Heart Association \\[NYHA\\] functional class III or IV);\n5. Patients with psychiatric disorders that affect study medication administration and evaluation;\n6. Contraindications to MRI examination (e.g., claustrophobia, presence of an implantable pacemaker, etc.);\n7. Patients unable to comply with follow-up examinations or other study procedures due to residential location or other reasons;\n8. Participation in other clinical trial projects.",{"count":58,"type":22},50,"6 Months","OBSERVATIONAL","The incidence of cerebral small vessel disease (CSVD) increases with age, affecting approximately 5% of individuals over 50 years old and nearly all individuals over 90 years old. CSVD is also the most important vascular factor contributing to cognitive decline, with 45% of dementia patients attributed to CSVD. Existing interventions are similar to secondary prevention strategies for cardiovascular and cerebrovascular diseases, and no specific therapies are currently available.\n\nCSVD-related cognitive impairment (CSVDCI) predominantly involves attention, processing speed, and executive functions, with relatively preserved memory function, and may be accompanied by non-cognitive clinical manifestations such as gait disturbances, emotional and behavioral disorders, and bladder dysfunction. Although CSVDCI can be classified under vascular cognitive impairment (VCI), there are certain differences in its clinical manifestations.\n\nIn summary, it is necessary to develop more targeted treatments for CSVD. We attempt to establish a \"symptom-tongue coating-gut microbiota-imaging\" system to provide data support for the subsequent exploration of CSVD treatments based on traditional Chinese medicine (TCM) syndrome differentiation and treatment.",[63,64,65],"Cerebral Small Vessel Diseases","Cognitive Impairment","Diffusion Tensor Imaging","2026-01-06",{"date":68,"type":40},"2026-01-15",{"date":70,"type":40},"2025-11-13",{"date":44,"type":22},{"name":46,"class":47},{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":79,"eligibilityCriteria":80,"healthyVolunteers":11,"sex":17,"minAge":81,"maxAge":82,"enrollmentInfo":83,"targetDuration":4,"studyType":23,"phases":85,"briefSummary":87,"conditions":88,"keywords":4,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":97,"locationsCount":48},"100613833","songling-xuemaikang-capsules-for-cerebral-small-vessel-disease-100613833","NCT07271732","Songling Xuemaikang Capsules for Cerebral Small Vessel Disease","Songling Xuemaikang Capsules for Cerebral Small Vessel Disease: A Randomized, Double-blind, Placebo-controlled, Multicenter Clinical Study","SXC-CSVD","Inclusion Criteria:\n\n1. Age 55-75 years (both inclusive);\n2. MRI has moderate to (1) severe white matter lesions (deep Fazekas score \\> 1 or paraventricular Fazekas score \\> 2 or modified Fazekas score \\> 1), or (2) mild white matter hyperintensity (deep Fazekas score = 1 or paraventricular Fazekas score = 2 or modified Fazekas score = 1) combined with more than 1 lacunar infarction;\n3. History of essential hypertension; Hypertension is defined as SBP consistently greater than 140 mmHg and\u002For DBP consistently greater than 90 mmHg, or those requiring clinical antihypertensive treatment.\n4. Meeting the diagnostic criteria for hyperactivity of liver yang pattern; Hyperactivity of liver yang pattern is defined as having at least three of the following six symptoms: headache, dizziness or vertigo, irritability, flushed face, red eyes, and yellow tongue coating.\n5. Functional independence in daily living (Modified Rankin Scale ≤2);\n6. Voluntary participation in the study and be willing to sign the Informed Consent Form.\n\nExclusion Criteria:\n\n1. Patients with acute ischemic stroke or acute intracranial hemorrhage (e.g., epidural hematoma, subdural hematoma, subarachnoid hemorrhage, intracerebral hemorrhage, etc.) or a history of cerebral infarction (non-lacunar) or intracranial hemorrhage within the past 3 months;\n2. Symptomatic stenosis of the middle cerebral artery and\u002For internal carotid artery (stenosis rate ≥50%), or asymptomatic stenosis of the middle cerebral artery and\u002For internal carotid artery (stenosis rate ≥70%);\n3. Untreated cerebrovascular malformations or intracranial aneurysms (diameter \\>3 mm);\n4. Significant non-vascular white matter lesions (e.g., multiple sclerosis, adult-onset leukoencephalopathy, metabolic encephalopathy, etc.);\n5. Patients with a history of cognitive impairment due to other causes (e.g., normal pressure hydrocephalus, Alzheimer's disease, Parkinson's disease, multiple sclerosis, encephalitis, etc.);\n6. A history of intracranial or intramedullary surgery within the past year;\n7. Severe hepatic, renal, or cardiac insufficiency (ALT or AST \\>2 times the upper limit of normal, or serum creatinine \\>1.5 times the upper limit of normal, or New York Heart Association \\[NYHA\\] functional class III or IV);\n8. Severe three-vessel coronary artery disease as shown by coronary computed tomography angiography or coronary angiography within 90 days or suffering from frequent angina;\n9. Refractory hyperglycemia uncontrolled by medication (fasting blood glucose \\>10 mmol\u002FL, or HbA1c \\>8.0%);\n10. Patients with severe diseases such as cancer and a life expectancy of less than 2 years;\n11. Patients with psychiatric disorders that affect study medication administration and evaluation;\n12. Previous allergy or intolerance to Songling Xuemaikang Capsules;\n13. Contraindications to MRI examination (e.g., claustrophobia, presence of an implantable pacemaker, etc.);\n14. Patients unable to comply with follow-up examinations or other study procedures due to residential location or other reasons;\n15. Participation in other clinical trial projects.","55 Years","75 Years",{"count":84,"type":22},90,[86],"NA","Cerebral small vessel disease (CSVD) is a common age-related microvascular disease related to the slow accumulation of damage to small arteries, veins, and capillaries. Hypertension is a risk factor for cerebrovascular disease, and its damage to the vascular endothelium is one of the key contributing factors to the pathogenesis of CSVD. CSVD has an insidious onset, and patients may exhibit no clinical symptoms in the early stage. Common clinical manifestations of chronic CSVD include vascular dementia, depression, gait disturbance, and abnormalities in swallowing and urinary functions. There is currently no specific treatment for CSVD.\n\nExisting studies have shown that Songling Xuemaikang capsule (SXC) combined with antihypertensive drugs exerted significant effects on systolic blood pressure (SBP), diastolic blood pressure (DBP), 24-hour SBP, and 24-hour DBP, while also improving symptoms of hypertension. Animal experiments have demonstrated that SXC can reduce apoptosis and alleviate cerebral ischemia-reperfusion injury, exerting neuroprotective effects. Additionally, a previously completed multicenter, randomized, double-blind, non-inferiority-designed clinical trial by the team, conducted in patients with primary hypertension, showed that SXC were non-inferior to losartan potassium in reducing diastolic blood pressure. Therefore, exploring the therapeutic potential of SXC in CSVD is highly necessary.\n\nThis project is a randomized, double-blind, placebo-controlled multicenter clinical study to investigate the clinical efficacy and safety of SXC in the treatment of hypertension with CSVD. A total of 90 subjects who met the subject screening criteria are planned to be enrolled, with 45 patients in the test group and 45 patients in the placebo group.",[89,63],"Hypertension","NOT_YET_RECRUITING","2025-12-06",{"date":93,"type":40},"2025-12-09",{"date":95,"type":22},"2025-12-10",{"date":44,"type":22},{"name":46,"class":47},{"id":99,"slug":100,"hasResults":11,"nctId":101,"briefTitle":102,"officialTitle":103,"acronym":104,"eligibilityCriteria":105,"healthyVolunteers":11,"sex":17,"minAge":106,"maxAge":107,"enrollmentInfo":108,"targetDuration":4,"studyType":23,"phases":110,"briefSummary":112,"conditions":113,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":116,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":122,"locationsCount":48},"100581990","phase-1-qingre-huatan-formula-for-the-prevention-of-early-neurological-deterioration-in-acute-ischemic-stroke-100581990","NCT06857487","Qingre Huatan Formula for the Prevention of Early Neurological Deterioration in Acute Ischemic Stroke","Efficacy and Safety of Qingre Huatan Formula for the Prevention of Early Neurological Deterioration in Patients With Acute Ischemic Stroke : A Randomized Double-blind Placebo-controlled Pilot Trial","QUIET","Inclusion Criteria:\n\n1. Inpatients diagnosed with acute ischemic stroke. Inpatients diagnosed of acute ischemic stroke.\n2. Meet the criteria of TCM phlegm-heat syndrome\n3. Patients at high-risk of END : Magnetic resonance imaging (MRI) reveals new ischemic lesions, with DWI-ASPECTS score ≤ 7, or presence of at least two risk factors of END.\n4. Acute ischemic stroke within 48 hours after onset.\n5. Aged 18-80 years, male or female.\n6. The patient or representative has signed informed consent.\n\nExclusion Criteria:\n\n1. Received or planned thrombolysis or endovascular therapy after onset.\n2. Suspected secondary stroke caused by brain tumor, brain trauma, hemopathy, etc.\n3. Already dependent in activities of daily living before the present acute stroke (defined as modified Rankin Scare score ≥2 )\n4. Diseases that cause motor dysfunction, including osteoarthritis, etc.\n5. Known severe liver or kidney dysfunction (alanine aminotransferase or aspartate transaminase \\> 2 times the upper limit of normal value, serum creatinine \\> 1.5 times the upper limit of normal value)\n6. Known severe aphasia or mental illness affecting clinical information collection and evaluation.\n7. Pregnancy, potential pregnancy or breastfeeding.\n8. Currently participating in other clinical trials.","18 Years","80 Years",{"count":109,"type":22},72,[111,25],"PHASE1","The purpose of this study is to assess the effectiveness and safety of Qingre Huatan formula versus placebo on preventing early neurological deterioration in patients with acute ischemic stroke within 48 hours after onset.",[114],"Acute Ischemic Stroke","2025-11-24",{"date":117,"type":40},"2025-12-01",{"date":119,"type":40},"2025-06-13",{"date":121,"type":22},"2026-10-29",{"name":46,"class":47},{"id":124,"slug":125,"hasResults":11,"nctId":126,"briefTitle":127,"officialTitle":128,"acronym":129,"eligibilityCriteria":130,"healthyVolunteers":11,"sex":17,"minAge":106,"maxAge":131,"enrollmentInfo":132,"targetDuration":4,"studyType":23,"phases":134,"briefSummary":135,"conditions":136,"keywords":137,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":141,"lastUpdatePostDateStruct":142,"startDateStruct":144,"completionDateStruct":146,"leadSponsor":148,"locationsCount":48},"100605529","phase-2-efficacy-and-safety-of-xinglou-chengqi-granule-for-acute-ischemic-stroke-100605529","NCT07163702","Efficacy and Safety of Xinglou Chengqi Granule for Acute Ischemic Stroke","Efficacy and Safety of Xinglou Chengqi Granule for Acute Ischemic Stroke (EXACT): a Multi-center, Randomized, Double-blinded, Dose-exploration Ⅱa Trial","EXACT","Inclusion Criteria:\n\n1. Inpatients diagnosed with acute ischemic stroke.\n2. Meet the criteria of TCM phlegm-heat and fu-organ excess syndrome.\n3. Acute ischemic stroke within 7 days after onset.\n4. 6 ≤ NIHSS \\\u003C20.\n5. Aged 18-70 years, male or female.\n6. The patient or representative has signed informed consent.\n\nExclusion Criteria:\n\n1. Suspected secondary stroke caused by brain tumor, brain trauma, hemopathy, etc.\n2. NIHSS Ⅰa ≥2.\n3. Already dependent in activities of daily living before the present acute stroke (defined as modified Rankin Scare score ≥2 )\n4. Received or planned thrombolysis or endovascular therapy after onset.\n5. Known severe liver or kidney dysfunction (alanine aminotransferase or aspartate transaminase \\> 2.5 times the upper limit of normal value, serum creatinine \\> 1.5 times the upper limit of normal value)\n6. With cancers or uncontrolled diabetes.\n7. The expected survival time is less than 3 months.\n8. Patients who have used other traditional Chinese medicine for treating acute ischemic stroke since stroke onset.\n9. Patients with severe mental disorders, dementia, or other comorbid diseases that may affect neurological function examination.\n10. With a history of alcohol or drug abuse or drug dependence.\n11. Those known to be allergic to the investigated drug or its components.\n12. Pregnancy, potential pregnancy, or breastfeeding.\n13. Currently participating in other clinical trials during the past 3 months.\n14. Those who are judged by researchers to have poor compliance or are not suitable for participating in this study for any other reason.","70 Years",{"count":133,"type":22},60,[25],"This is a Ⅱa clinical trial. The purpose of this study is to preliminarily explore the optimal dosage of Xinglou Chengqi Granules in the treatment of acute ischemic stroke and to evaluate the efficacy and safety of Xinglou Chengqi Granules for acute ischemic stroke.",[114],[138,139,140],"acute ischemic stroke","Xinglou Chengqi granules","randomized controlled trial","2025-09-02",{"date":143,"type":40},"2025-09-09",{"date":145,"type":22},"2025-10-01",{"date":147,"type":22},"2026-09-30",{"name":46,"class":47},{"id":150,"slug":151,"hasResults":11,"nctId":152,"briefTitle":153,"officialTitle":154,"acronym":155,"eligibilityCriteria":156,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":157,"enrollmentInfo":158,"targetDuration":4,"studyType":23,"phases":160,"briefSummary":161,"conditions":162,"keywords":166,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":170,"lastUpdatePostDateStruct":171,"startDateStruct":173,"completionDateStruct":175,"leadSponsor":177,"locationsCount":48},"100587811","phase-1-efficacy-of-fuzheng-tongfu-jiedu-prescription-for-treating-gastrointestinal-dysfunction-associated-with-sepsis-100587811","NCT06933238","Efficacy of Fuzheng Tongfu Jiedu Prescription for Treating Gastrointestinal Dysfunction Associated With Sepsis","The Clinical Effect and Mechanism of Fuzheng Tongfu Jiedu Prescription Regulating Cell Pyrodeath in the Treatment of Gastrointestinal Dysfunction in Sepsis Based on mtDNA\u002FNLRP3\u002FCaspase-1\u002FGSDMD Signaling Pathway","FZTFJD","Inclusion Criteria:\n\n1. Clinical diagnosis of sepsis-induced gastrointestinal dysfunction with Acute AGI grade I-III.\n2. 50-90 years old, regardless of gender.\n3. Sequential Organ Failure Assessment (SOFA) score ≥ 2.\n4. Diagnosed with sepsis-induced gastrointestinal dysfunction within 24 hours.\n5. Voluntary participation with signed informed consent.\n\nExclusion Criteria:\n\n1. ICU length of stay ≤ 3 days (due to death, discharge, or transfer), rendering gastrointestinal function evaluation unfeasible.\n2. Patients with allergies or allergic constitution to the investigational herbal medications.\n3. Inability to measure intra-abdominal pressure or abdominal circumference due to obesity (weight \\> 150 kg), trauma, or surgical factors.\n4. Severe organic diseases: lower gastrointestinal bleeding, malignancies, cirrhosis, chronic renal failure (uremic stage), hematologic disorders, HIV, etc.\n5. History of gastrointestinal surgery.\n6. Long-term use of corticosteroids or immunosuppressants.\n7. Severe psychiatric disorders or inability to cooperate with trial protocols.\n8. Participation in other clinical trials within 30 days.\n9. Pregnant or lactating women.\n10. Participated in other clinical studies in the past 3 months.","90 Years",{"count":159,"type":22},70,[111,25],"This study is a single-center, randomized, double-blind, placebo-controlled trial.",[163,164,165],"Sepsis Abdominal","Gastrointestinal Dysfunction","Traditional Chinese Medicine",[167,30,168,169],"gastrointestinal dysfunction","Traditional Chinese medicine","Fuzheng Tongfu Jiedu Decoction","2025-04-11",{"date":172,"type":40},"2025-04-18",{"date":174,"type":22},"2025-04-25",{"date":176,"type":22},"2026-06-30",{"name":46,"class":47},{"id":179,"slug":180,"hasResults":11,"nctId":181,"briefTitle":182,"officialTitle":182,"acronym":4,"eligibilityCriteria":183,"healthyVolunteers":184,"sex":17,"minAge":18,"maxAge":157,"enrollmentInfo":185,"targetDuration":4,"studyType":60,"phases":4,"briefSummary":187,"conditions":188,"keywords":190,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":193,"lastUpdatePostDateStruct":194,"startDateStruct":196,"completionDateStruct":198,"leadSponsor":199,"locationsCount":48},"100566454","correlation-between-pla-levels-and-disease-severity-in-patients-with-sepsis-cardiac-insufficiency-100566454","NCT06655389","Correlation Between PLA Levels and Disease Severity in Patients With Sepsis Cardiac Insufficiency","Inclusion Criteria:\n\n* Sepsis cardiac insufficiency group\n\n  1. From April 2024 to December 2026, in the first ICU area of Dongzhimen Hospital, Beijing University of Chinese Medicine, Hospitalized patients in Zone II;\n  2. consistent with the diagnosis of sepsis cardiac insufficiency;\n  3. Age ≥ 50 and ≤ 90 years old;\n  4. SOFA score≥ 2 points;\n  5. Within 24 hours of the diagnosis of cardiac insufficiency in sepsis;\n  6. The patient or his\u002Fher family members sign the informed consent form. Healthy subjects\n\n  \u003C!-- -->\n\n  1. Aged ≥ 50 and ≤ 90 years old, permanent residents of Beijing community;\n  2. Good health (blood routine, liver and kidney function, blood lipids, blood coagulation, no obvious abnormalities, no diagnosis cardiac insufficiency, acute coronary syndrome, old myocardial infarction, or cardiomyopathy);\n  3. There is no history of long-term use of drugs that affect platelet function and coagulation function, and those who are willing to cooperate with the test Crowd;\n  4. The subject himself signed the informed consent form.\n\nExclusion Criteria:\n\n* 1\\) Diagnosed with acute coronary syndrome, old myocardial infarction, and coronary heart disease revascularization of patients; (2) Cardiac insufficiency due to cardiomyopathy, such as hypertrophic cardiomyopathy, dilated cardiomyopathy, myocardial amyloidosis, diabetic cardiomyopathy, hypothyroidic cardiomyopathy, etc.; (3) Due to heart knots Cardiac insufficiency caused by structural abnormalities, arrhythmias, cor pulmonale, nephroheart syndrome, etc.; (4) Impact Survival of severe primary diseases, including: uncontrolled malignant tumors that have metastasized in multiple places and cannot be resected, and blood disease, novel coronavirus infection and HIV, etc.; (5) Liver and kidney dysfunction with a single SOFA score of ≥3 points in liver or kidney handicappers; (6) Those who have been continuously using immunosuppressants or organ transplantation in the past 6 months; (7) 7 consecutive days prior to enrollment Those who have used corticosteroids, converted to methylprednisolone dose≥ 20mg\u002Fday; (8) Pregnant and lactating women; (9) Take or Injection of drugs that affect platelet function and coagulation function; (10) Those who have participated in other clinical trials within 30 days.",true,{"count":186,"type":22},30,"Sepsis cardiac insufficiency is characterized by high morbidity and mortality. Studies have shown an association between elevated PLA levels in patients with sepsis and clinical outcomes of cardiac dysfunction. This study will explore the correlation between circulating PLA levels and organ dysfunction and disease severity in SIMD patients in the form of a cross-sectional study.",[189],"Sepsis Cardiac Insufficiency",[191,192],"Sepsis cardiac insufficiency","PLA","2024-10-22",{"date":195,"type":40},"2024-10-23",{"date":197,"type":40},"2024-05-01",{"date":44,"type":22},{"name":46,"class":47},{"id":201,"slug":202,"hasResults":11,"nctId":203,"briefTitle":204,"officialTitle":205,"acronym":4,"eligibilityCriteria":206,"healthyVolunteers":11,"sex":17,"minAge":106,"maxAge":107,"enrollmentInfo":207,"targetDuration":4,"studyType":60,"phases":4,"briefSummary":209,"conditions":210,"keywords":4,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":212,"lastUpdatePostDateStruct":213,"startDateStruct":215,"completionDateStruct":217,"leadSponsor":219,"locationsCount":48},"100552237","molecular-characteristics-of-phlegm-heat-syndrome-in-ischemic-stroke-100552237","NCT06470477","Molecular Characteristics of Phlegm-heat Syndrome in Ischemic Stroke","Molecular Characteristics of Phlegm-heat Syndrome in Ischemic Stroke: A Cohort Study","Inclusion Criteria:\n\n* Acute ischemic stroke.\n* Symptom onset within 72 hours.\n* Diagnosis of phlegm-heat syndrome or non-phlegm-heat syndrome.\n* Male or female ≥18 years and ≤ 80 years.\n* With written informed consent.\n\nExclusion Criteria:\n\n* Acute infectious diseases or acute exacerbations of chronic diseases within one month before enrollment.\n* Patients has previous stroke.\n* Other conditions that lead to motor dysfunction (e.g., severe osteoarthritis, rheumatoid arthritis).\n* Renal or hepatic insufficiency, tumors, immune diseases, severe underlying diseases.\n* Other conditions that affect the collection and evaluation of clinical information (e.g., severe aphasia, mental illness).",{"count":208,"type":22},84,"The molecular characteristics of ischemic stroke with phlegm-heat syndrome and candidate biomarkers were identified based on multi-omics data. The main purpose of this study is to validate the molecular characteristics and biomarkers of phlegm-heat syndrome in ischemic stroke, and to demonstrate the association of biomarkers with clinical outcomes.",[211],"Ischemic Stroke, Acute","2024-06-17",{"date":214,"type":40},"2024-06-24",{"date":216,"type":22},"2024-06-20",{"date":218,"type":22},"2024-12-31",{"name":46,"class":47},{"id":221,"slug":222,"hasResults":11,"nctId":223,"briefTitle":224,"officialTitle":224,"acronym":4,"eligibilityCriteria":225,"healthyVolunteers":184,"sex":17,"minAge":18,"maxAge":107,"enrollmentInfo":226,"targetDuration":4,"studyType":60,"phases":4,"briefSummary":209,"conditions":228,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":212,"lastUpdatePostDateStruct":229,"startDateStruct":230,"completionDateStruct":232,"leadSponsor":233,"locationsCount":48},"100487377","molecular-network-characteristics-of-phlegm-heat-syndrome-in-ischemic-stroke-based-on-multi-omics-integrated-analysis-100487377","NCT05626296","Molecular Network Characteristics of Phlegm-heat Syndrome in Ischemic Stroke Based on Multi-omics Integrated Analysis","Inclusion Criteria:\n\n* Acute ischemic stroke, were confirmed by magnetic resonance imaging (MRI).\n* Symptom onset within 72 hours.\n* Diagnosis of phlegm-heat syndrome or non-phlegm-heat syndrome.\n* Male or female ≥ 50 years and ≤ 80 years.\n* With written informed consent.\n\nExclusion Criteria:\n\n* Planned or already receiving intravenous thrombolysis or endovascular treatment.\n* Acute infectious diseases or acute exacerbations of chronic diseases within one month before enrollment.\n* Patients with previous stroke.\n* Renal or hepatic insufficiency, tumors, immune diseases, severe underlying diseases.\n* Other conditions that may affect the collection and evaluation of clinical information (e.g., severe aphasia, mental illness).",{"count":227,"type":22},24,[211],{"date":216,"type":40},{"date":231,"type":40},"2022-11-14",{"date":218,"type":22},{"name":46,"class":47},{"id":235,"slug":236,"hasResults":11,"nctId":237,"briefTitle":238,"officialTitle":239,"acronym":240,"eligibilityCriteria":241,"healthyVolunteers":11,"sex":17,"minAge":106,"maxAge":4,"enrollmentInfo":242,"targetDuration":244,"studyType":60,"phases":4,"briefSummary":245,"conditions":246,"keywords":248,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":251,"lastUpdatePostDateStruct":252,"startDateStruct":254,"completionDateStruct":256,"leadSponsor":257,"locationsCount":258},"100503336","suhexiang-pill-for-acute-ischemic-stroke-a-registry-study-100503336","NCT05833932","Suhexiang Pill for Acute Ischemic Stroke: A Registry Study","Suhexiang Pill for Acute Ischemic Stroke: A Prospective Registry Study of Real-world Data","SUNRISE","Inclusion Criteria:\n\n* Acute ischemic stroke within 7 days of symptom onset.\n* Age ≥ 18\n* Patient who has received Suhexiang Pill treatment\n* Patient or legally authorized representative has signed informed consent.\n\nExclusion Criteria:\n\n* Be allergic to Suhexiang Pill\n* Known to be pregnant or breastfeeding.\n* With conditions that render outcomes or follow-up unlikely to be assessed.",{"count":243,"type":22},1000,"1 Year","The primary purpose of this study is to investigate the effectiveness and safety of the Suhexiang Pill for patients with acute ischemic stroke in real-world settings.",[247],"Ischemic Stroke",[138,249,250],"traditional Chinese medicine","registry study","2024-06-10",{"date":253,"type":40},"2024-06-11",{"date":255,"type":40},"2023-06-01",{"date":218,"type":22},{"name":46,"class":47},2,{"id":260,"slug":261,"hasResults":11,"nctId":262,"briefTitle":263,"officialTitle":263,"acronym":4,"eligibilityCriteria":264,"healthyVolunteers":11,"sex":17,"minAge":106,"maxAge":265,"enrollmentInfo":266,"targetDuration":268,"studyType":60,"phases":4,"briefSummary":269,"conditions":270,"keywords":272,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":277,"lastUpdatePostDateStruct":278,"startDateStruct":280,"completionDateStruct":282,"leadSponsor":284,"locationsCount":4},"100471185","demyelinating-diseases-of-the-central-nervous-system-registry-for-patients-with-traditional-chinese-medicine-date-tcm-100471185","NCT05415579","Demyelinating Diseases of the Central Nervous System Registry for Patients With Traditional Chinese Medicine (DATE-TCM)","Inclusion Criteria:\n\n* Male or female participants with aged 18-65 years old; Diagnosis of DDC including multiple sclerosis (MS), Neuromyelitis optica spectrum disorder (NMOSD), and myelin oligodendrocyte glycoprotein-associated disease(MOGAD) according to relevant criteria or consensus; Patients who receive or are willing to receive TCM treatment including the Chinese herbal medicine, acupuncture, moxibustion, massage, taiji, and qigong; Informed written consent obtained from the patient, and\u002For his\u002Fher legally authorized representatives.\n\nExclusion Criteria:\n\n* Refusal to give informed consent; Malignancies, infectious diseases (HBV, HCV, HIV, etc.), congenital or acquired severe immunodeficiency, significant cardiovascular, pulmonary, and hepatic diseases or conditions; Mental disturbance or severe cognitive impairment impeding necessary information gathering and assessment.","65 Years",{"count":267,"type":22},2000,"5 Years","Demyelinating Diseases of the Central Nervous System Registry for Patients with Traditional Chinese Medicine (DATE-TCM) is an observational study aiming to better define the multidimensional (epidemiologic, demographic and clinical) characteristics of Demyelinating Diseases of the Central Nervous System (DDC) patients receiving Traditional Chinese medicine (TCM) treatment, the type and long-term safety and effectiveness of TCM in DDC populations, as well as the interaction of TCM treatment and disease-modifying therapy in the management of DDC.",[271],"Demyelinating Diseases of the Central Nervous System (DDC)",[273,274,275,276],"Demyelinating Diseases of the Central Nervous System","Multiple sclerosis","Neuromyelitis optica spectrum disorder","Myelin oligodendrocyte glycoprotein associated disorder","2022-06-09",{"date":279,"type":40},"2022-06-13",{"date":281,"type":22},"2022-06-20",{"date":283,"type":22},"2030-05-31",{"name":46,"class":47},{"id":286,"slug":287,"hasResults":11,"nctId":288,"briefTitle":289,"officialTitle":289,"acronym":290,"eligibilityCriteria":291,"healthyVolunteers":11,"sex":17,"minAge":106,"maxAge":4,"enrollmentInfo":292,"targetDuration":268,"studyType":60,"phases":4,"briefSummary":293,"conditions":294,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":296,"lastUpdatePostDateStruct":297,"startDateStruct":299,"completionDateStruct":301,"leadSponsor":303,"locationsCount":48},"100430461","china-amyotrophic-lateral-sclerosis-registry-of-patients-with-traditional-chinese-medicine-100430461","NCT04885374","China Amyotrophic Lateral Sclerosis Registry of Patients With Traditional Chinese Medicine","CARE-TCM","Inclusion Criteria:\n\n* Patients aged 18 years and older.\n* Patients with possible, laboratory supported probable, probable, or definite ALS according to the revised El Escorial criteria.\n* ALS patients treated with traditional Chinese medicine.\n\nExclusion Criteria:\n\n* Patients who refuse informed consent.",{"count":267,"type":22},"A multi-center registration study of clinical characteristics of amyotrophic lateral sclerosis (ALS) patients with traditional Chinese medicine (TCM).",[295],"Amyotrophic Lateral Sclerosis","2021-05-08",{"date":298,"type":40},"2021-05-13",{"date":300,"type":40},"2021-03-01",{"date":302,"type":22},"2028-03-01",{"name":46,"class":47},""]